ImmuPharma plc IMM

ImmuPharma PLC (AIM:IMM, FRA:25I) has signed up Kymos Group as its bioanalytical partner for diabetes drug Kapiglucagon. That completes the outsourced team needed to file for human trials in the US. ValiRx PLC (AIM:VAL, FRA:EAJF) is set to get a second European patent for its cancer-killing peptide from subsidiary Cytolytix. It's targeting triple negative breast cancer and is in talks with a major pharma company. Tertiary Minerals PLC (AIM:TYM, OTC:TTIRF, FRA:TMU) has drilled some strong copper and silver hits at its Mushima North project in Zambia. Lab results are due in the coming weeks, wit

Thermo Fisher Scientific (NYSE:TMO) has been selected by ImmuPharma as the key drug product and contract development manufacturer for its Kapiglucagon diabetes treatment program. The partnership covers development and manufacturing support for Kapiglucagon, an experimental therapy aimed at addressing diabetes. This agreement adds a new project to Thermo Fisher Scientific’s pharmaceutical services portfolio, focused on complex drug development work. For investors tracking Thermo Fisher...

Seeing Machines (AIM:SEE) has won a new driver monitoring contract with a European carmaker worth around $5 million in lifetime revenue, just as new EU safety rules make the technology mandatory on new vehicles. Production starts in 2028, with the system built into a rear-view mirror for easy deployment across multiple platforms. Frontier IP (LSE:FIPP) says portfolio company Cambridge Raman Imaging has secured a €400,000 European grant to scale up its AI-powered pharmaceutical quality control technology. The company has also appointed a China-based distributor with over 100 customers globally.

Tower Resources (AIM:TRP) has won formal approval from Namibia's government for its PEL96 farm-out to Prime Global Energies, clearing the final hurdle on a deal first announced back in January 2025. The company will now issue a notice of completion, with full sign-off expected shortly. Tertiary Minerals (AIM:TYM) has started drilling at its Target A1 silver discovery at the Mushima North project in Zambia, its biggest programme there to date. The target could hold up to 58 million ounces of silver equivalent, and the company's also testing two further prospects nearby. Rome Resources (AIM:RMR)

Tower Resources (AIM:TRP) has raised £400,000 to bolster working capital while it waits on government approvals in Namibia and Cameroon. The company says both farm-out deals could complete as early as July. Buccaneer Energy (AIM:BUCE) says its proved reserves rose 18% in an independent review tied to its bank credit facility. The borrowing base was confirmed at $4.45 million, with more growth expected as production ramps up. Light Science Technologies (AIM:LST) has secured up to £1.66 million in orders for its passive fire protection division since April's RLUK Injection acquisition. The compa

Empire Metals Ltd (AIM:EEE, OTCQX:EPMLF) has delivered strong early results from its biggest ever drilling campaign at the Pitfield titanium project in Western Australia. Multiple thick, near-surface intercepts above 7% TiO₂ have confirmed a high-grade core that management calls "a defining moment for Pitfield." ImmuPharma PLC (AIM:IMM, FRA:25I) is advancing its Kapiglucagon diabetes drug towards US human trials, engaging specialist consultancy tranScrip to prepare for an FDA pre-IND meeting. The drug targets next-generation artificial pancreas systems in a market forecast to hit $13.6 billion

Rome Resources Plc (AIM:RMR, FRA:33R) says drilling at its Kalayi prospect in the Democratic Republic of Congo has delivered its strongest tin intercepts so far. Early readings point to high-grade mineralisation, with a resource update expected once assays land. Great Southern Copper PLC (LSE:GSCU, FRA:E9E) has identified new gold-copper targets at its Viuda prospect in Chile. A large concealed anomaly could drive the next phase of drilling in the second quarter. European Green Transition PLC (AIM:EGT) has built a £126 million pipeline in wind repowering projects. The company says demand is ri

ImmuPharma (AIM:IMM, FRA:25I) says it's on track to deliver a licensing deal for its lead asset P140 this year. The company has also fast-tracked Kapiglucagon, a next-gen diabetes treatment, backed by funding from Lanstead Capital. Ilika (AIM:IKA, OTCQX:ILIKF, FRA:I8A) has had its Goliath solid-state batteries tested under battlefield conditions — including live-fire testing. The results demonstrated the inherent safety advantages of Ilika’s solid-state battery technology compared to traditional lithium-ion alternatives Coinsilium (AQSE:COIN, OTCQB:CINGF, FRA:5CT) is betting on prediction mark

ImmuPharma PLC (AIM:IMM, FRA:25I) CEO Tim McCarthy joined Stephen Gunnion in the Proactive studio to discuss the company's latest developments, including progress on its lead asset P140, a newly accelerated program for Kapiglucagon, and recent fundraising activity. McCarthy emphasised that P140 remains the company’s primary focus, with ongoing licensing discussions described as highly active. He stated, “We are delivering a deal this year. We're confident of doing that,” highlighting continued engagement with multiple potential partners, including new parties that have approached the company s

Empire Metals Ltd (AIM:EEE, OTCQX:EPMLF) says new drilling confirms a high-grade zone at its Pitfield titanium project in Australia. A bigger drill campaign is underway, with an updated resource expected in the third quarter. Atlantic Lithium Ltd (AIM:ALL, ASX:A11, OTCID:ALLIF) has secured around $16 million to push its Ewoyaa project in Ghana forward. The funding brings in local pension funds and supports key milestones toward production. ImmuPharma PLC (AIM:IMM, FRA:25I) is raising up to £7.5 million to develop a new Type 1 diabetes treatment. It also says a licensing deal for its lead drug